Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of xerostomia and Sjögren's syndrome.
Medical uses
Cevimeline is used in the treatment of
xerostomia (dry mouth)
and Sjögren's syndrome.
It increases the production of saliva.
Side effects
Known side effects include
nausea,
vomiting,
diarrhea, excessive
sweating,
rash,
headache,
runny nose,
cough,
drowsiness,
,
blurred vision, and
insomnia.
Contraindications include asthma and angle closure glaucoma.
Mechanism of action
Cevimeline is a cholinergic agonist.
It has a particular effect on M
1 and M
3 receptors.
By activating the M
3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the
, thereby alleviating dry mouth.
See also
-
Pilocarpine — a similar parasympathomimetic medication for dry mouth (xerostomia)
-
Bethanechol — a similar muscarinic parasympathomimetic with longer-lasting effect
External links
